Savarirayan, R. Et Al. 2020. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. LANCET , vol.396, no.10252 , 684-692.

Savarirayan, R., Tofts, L., Irving, M., Wilcox, W., Bacino, C. A., Hoover-Fong, J., ... Ullot Font, R.(2020). Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. LANCET , vol.396, no.10252, 684-692.

Savarirayan, Ravi Et Al. "Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial," LANCET , vol.396, no.10252, 684-692, 2020

Savarirayan, Ravi Et Al. "Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial." LANCET , vol.396, no.10252, pp.684-692, 2020

Savarirayan, R. Et Al. (2020) . "Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial." LANCET , vol.396, no.10252, pp.684-692.

@article{article, author={Ravi Savarirayan Et Al. }, title={Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial}, journal={LANCET}, year=2020, pages={684-692} }